You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和元生物(688238.SH):隨着臨港基地產能逐步釋放 將推動訂單和收入規模快速增長
格隆匯 04-24 16:05

格隆匯4月24日丨有投資者向和元生物(688238.SH)提問:由於新建產能,今年利潤增速是否不及收入增長?

和元生物回覆:公司臨港大規模基地建設投入較大,今年預計下半年投產,固定資產根據業務需求分期投入運行,相關資產的折舊、攤銷費用將有一定增加;同時由於基因治療屬於技術密集型的新興領域,CRO/CDMO行業的技術具有門檻高、更新快的特點,公司將持續圍繞基因治療載體的開發技術、生產工藝及質控技術佈局,不斷加大研發投入,預計均將會短期內帶來利潤的波動影響。隨着臨港基地產能逐步釋放,將推動公司訂單和收入規模的快速增長,產能利用率提升後,獲利能力也將進一步體現。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account